Serum calcium (corrected for albumin) level at or below the ULN range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment) prior to study therapy initiation
Uncontrolled hypercalcemia (ionized calcium >. millimoles per liter [mmol/L], calcium > milligrams per deciliter [mg/dL], or corrected calcium greater than the upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
Serum calcium (corrected for albumin) level at or below the ULN (treatment of hypercalcemia is allowed and participant may enroll if hypercalcemia returns to normal with standard treatment).
Uncontrolled hypercalcemia (> . mmol/L ionized calcium or calcium[Ca] >  mg/dL or corrected serum calcium > ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab\r\n* Subjects who are receiving bisphosphonate therapy or denosumab specifically to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible\r\n* Subjects who are receiving denosumab prior to enrollment must be willing and eligible to receive a bisphosphonate instead while in the study
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratorys normal parameters
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
Hypercalcemia: serum calcium > . mg/ ml or
Serum calcium (corrected for albumin) level above the ULN range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment).
Total calcium (corrected for serum albumin) within institutional normal limits, or =< grade  according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version . if judged clinically not significant by the investigator (bisphosphonate use for malignant hypercalcemia control is not allowed)
Total calcium (corrected for serum albumin) within normal limits (ongoing requirement for bisphosphonate to control malignant hypercalcemia is not allowed but prophylactic use of bisphosphonate to prevent skeletal complication of bone metastasis is allowed)
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
Uncontrolled hypercalcemia (greater than [>] . millimoles per liter [mmol/L] ionized calcium or Ca >  milligrams per deciliter [mg/dL] or corrected serum calcium > upper limits of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
Pre-existing hypercalcemia (defined as baseline serum calcium above the institutional ULN, corrected for albumin level if albumin is not within institutional limits of normal); the use of supplemental calcium is prohibited while on study
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed; the use of denosumab [Xgeva] is permitted)
Total calcium (corrected for serum albumin) within normal limits (biphosphonate use for malignant hypercalcemia control is not allowed)
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
Serum calcium (corrected for serum albumin) or ionized calcium >= lower limit of normal (LLN) (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with standard treatment)
Total calcium (corrected for serum albumin) within normal limits (bisphosphonate use for malignant hypercalcemia control is not allowed)
Corrected calcium within normal limits, previous hypercalcemia allowed
Hypercalcemia (serum calcium in excess of laboratory upper limit of normal [ULN])
Subjects may be taking calcium supplements or have previous history of hypercalcemia
Hypercalcemia (serum calcium greater than [>]. millimoles per liter [mmol/L] [> milligram per deciliter {mg/d
Hypercalcemia (serum calcium in excess of laboratory upper limit normal [ULN])
Uncontrolled hypercalcemia (> . mmol/L ionized calcium or calcium >  mg/dL or corrected serum calcium > upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy; patients who are receiving denosumab must discontinue denosumab use and replace it with a bisphosphonate instead while on study; patients receiving a bisphosphonate for skeletal metastases are not excluded and can continue treatment
Pre-existing hypercalcemia (defined as baseline serum calcium above the institutional ULN, corrected for albumin level if albumin is not within institutional limits of normal)\r\n* The use of supplemental calcium or supplements containing calcium is prohibited during the treatment period of this clinical trial
